Cancer Cell: A big breakthrough! Wu Jiarui/Zeng Wei/Zhang Wei obtained comprehensive histological data on metastatic colorectal cancer for the first time, laying the foundation for accurate treatment.

Despite increasing progress in treatment, colorectal cancer (CRC), especially metastatic CRC, remains a high mortality rate in cancer-related deaths.
currently, only DNA misalmed repair states, RAS mutations and BRAF mutation states, affect clinical decision-making.
is expected to help improve the multi-group characteristics of treatment that will lead to precise and personalized care.
combination of genomics and proteomics could provide more insights that genome analysis alone might not be able to decipher.
September 3, 2020, Wu Jiarui, Zeng Wei, and Zhang Wei of the Naval Medical University of the Chinese Academy of Sciences published an online newsletter entitled "Integrated Omics of Metastatic Colorectal Cancer" on Campus Cell. The study, which integrates genomics, proteomics and phosphorylation proteomics from 146 patients in the Chinese colorectal cancer (CRC) cohort, included metastatic CRC (mCRC).
proteomics analysis can distinguish between three CRC subsypes, characterized by different clinical prognostic and molecular characteristics.
proteomics and phosphate proteomics analysis of primary tumors alone can successfully distinguish between metastasis stoves.
metastasis tissue showed a high genetic similarity to primary tumors, but not at proteomics level, and kinase network analysis showed significant heterogeneity between primary colorectal tumors and liver metastasis.
Tests with heterogeneic transplant drugs from 31 primary and metastasis tumors showed a personalized response, which can also be predicted through kinase-substrate network analysis, regardless of whether the tumor carries mutations in the genes of the targeted drug.
this study provides valuable resources for a better understanding of mCRC and has the potential for clinical application.
(CRC) is the world's fourth deadliest cancer, killing nearly 900,000 people each year.
aging, poor eating habits and lifestyles all increase the risk of CRC, with different prognosmations defined by their molecules.
previous studies in TCGA and CTAC colorectal cancer studies have characterized multi-histological characteristics and molecular heterogeneity.
, however, these studies focus more on non-transfer status among non-Asian populations.
progress in treatment, CRC, especially metastasis CRC, still has a high mortality rate among cancer-related deaths.
currently, only DNA misalmed repair states, RAS mutations and BRAF mutation states, affect clinical decision-making.
is expected to help improve the multi-group characteristics of treatment that will lead to precise and personalized care.
combination of genomics and proteomics could provide more insights that genome analysis alone might not be able to decipher.
the model of this article (from Canser Cell) here, the study describes the integration of genomics, proteomics, and phosphate proteomics in metastasis CRC from the Chinese queue.
analysis of multi-histological data shows that subsypes and metastasis have obvious proteomics and phosphate proteomics characteristics.
of kinase-substrates was identified as an accurate indicator of potential therapeutic drug reactions.
, the findings provide a wealth of resources, including promising goals and treatment evaluations for CRC.
.